EUVIMEDEUVIMED entdecken
Crossref

Novel benzimidazole‐linked (thio)barbiturates as non‐hydroxamate HDAC6 inhibitors targeting leukemia: Design, synthesis, and structure–activity relationship

Reda El-Sayed Mansour, Hanan Gaber Abdulwahab iD, Hend M El-Sehrawi

Archiv der Pharmazie · 2023

DOI: 10.1002/ardp.202200433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2023. Verfasst von Reda El-Sayed Mansour und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Based on the well‐established pharmacophoric features required for histone deacetylase (HDAC) inhibition, novel easy‐to‐prepare benzimidazole‐linked (thio)barbiturate derivatives were designed and synthesized as HDAC6 inhibitors. The proposed structures of the title compounds were confirmed based on their spectral data and elemental analyses. The newly synthesized compounds were screened in vitro against HDAC6. All tested compounds showed potent HDAC6 inhibition at the nanomolar level. Several compounds displayed a remarkable HDAC6 inhibitory activity (IC 50 = 48.85–75.62 nM), superior to that of the reference drug suberoylanilide hydroxamic acid (SAHA; IC 50 = 91.73 nM). The most potent derivatives were further assessed for their in vitro anticancer activity against two human leukemia cell lines. Thiobarbiturate 3e was two times more potent than SAHA against the tested cells. The detailed structure–activity relationship was also described. Furthermore, molecular docking simulation revealed the ability of the title compounds to chelate the catalytic Zn +2 ion located within the binding pocket of HDAC6. In silico evaluation of physicochemical properties indicated that the target compounds are promising candidates in terms of pharmacokinetic aspects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLeukemiaHumansStructure-Activity RelationshipMolecular Docking SimulationHistone Deacetylase InhibitorsCell Line, TumorHydroxamic AcidsVorinostatBarbituratesBenzimidazolesDrug DesignCell ProliferationDrug Screening Assays, AntitumorHistone Deacetylase 6

Stichwörter der Autor:innen

(thio)barbituric acidHDAC6 inhibitorbenzimidazolecytotoxicityleukemia

Substanzen

Antineoplastic AgentsHistone Deacetylase InhibitorsHydroxamic AcidsVorinostatBarbituratesBenzimidazolesHDAC6 protein, humanHistone Deacetylase 6

Autor:innen und Institutionen

  • Department of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.

ORCID-Profile: Hanan Gaber Abdulwahab

Zitieren

APA

Mansour, R. E., Abdulwahab, H. G., & El-Sehrawi, H. M. (2023). Novel benzimidazole‐linked (thio)barbiturates as non‐hydroxamate HDAC6 inhibitors targeting leukemia: Design, synthesis, and structure–activity relationship. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202200433

Vancouver

Mansour RE, Abdulwahab HG, El-Sehrawi HM. Novel benzimidazole‐linked (thio)barbiturates as non‐hydroxamate HDAC6 inhibitors targeting leukemia: Design, synthesis, and structure–activity relationship. Archiv der Pharmazie. 2023. doi:10.1002/ardp.202200433

BibTeX
@article{Mansour2023,
  author = {Mansour, Reda El-Sayed and Abdulwahab, Hanan Gaber and El-Sehrawi, Hend M},
  title = {Novel benzimidazole‐linked (thio)barbiturates as non‐hydroxamate HDAC6 inhibitors targeting leukemia: Design, synthesis, and structure–activity relationship},
  journal = {Archiv der Pharmazie},
  year = {2023},
  doi = {10.1002/ardp.202200433}
}
Kostenlos starten →